En la Selección de artículos colaboró el Dr. Joao Baptista de Palma





1.      Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Recurrence. Pág. 73-81.


2.   A Limited-Versus-Extensive Staging Strategy for Small Cell Prostate Cancer. Pág. 87-93.


3.      Sequencing Ipilimumab Immunotherapy Before or After Chemotherapy (Nab-Paclitaxel and Bevacizumab) for the Treatment of BRAFwt (BRAF Wild-Type) Metastatic Malignant Melanoma. Pág. 115-121.


4.      Expanding the Spectrum of Radiation Necrosis After Stereotactic Radiosurgery (SRS) for Intracranial Metastases From Lung Cancer. Pág. 128-132.


5.      Genomic and Molecular Abnormalities in Gynecologic Clear Cell Carcinoma. Pág. 139-145.


            ANNALS OF SURGICAL ONCOLOGY 2020 27 (3)


6.     Clinicopathologic Characteristics of Oligometastases from Esophageal Cancer and Long-Term Outcomes of Resection.Pág. 651-659.


7.      Utility of Radiation After Neoadjuvant Chemotherapy for Surgically Resectable Esophageal Cancer. Pág. 662-670.


8.      Impact of Lymphadenectomy on Survival After Unimodality Transthoracic Esophagectomy for Adenocarcinoma of Esophagus. Pág. 692-700.


9.      Surgical and Surgeon-Related Factors Related to Long-Term Survival in Esophageal Cancer: A Review. Pág. 718-723.


10.     The Landmark Series: Axillary Management in Breast Cancer. Pág. 724-729.


11.     Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Pág. 765-771.


12.     Predictors of Anastomotic Failure After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Technique Matter?. Pág. 783-792.


13.     The Suggestion of Revised Criteria for Endoscopic Resection of Differentiated-Type Submucosal Gastric Cancer. Pág. 795-801.


14.     Long-Term Survival after Minimally Invasive Versus Open Gastrectomy for Gastric Adenocarcinoma: A Propensity ScoreMatched Analysis of Patients in the United States and China. Pág. 802-811.


15.     Perioperative Blood Transfusion is Associated with Postoperative Systemic Inflammatory Response and Poorer Outcomes Following Surgery for Colorectal Cancer. Pág. 833-843.


16.     Fong’s Score in the Era of Modern Perioperative Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial. Pág. 877-885.


17.     Conservative Re-excision is a Safe and Simple Alternative to Radical Resection in Revision Surgery for Dermatofibrosarcoma Protuberans. Pág. 919-923.


18.     Neurologic Complications of Melanoma. Pág. 477-486.


19.     Fertility Preservation Before Breast Cancer Treatment Appears Unlikely to Affect Disease-Free Survival at a Median Follow-Up of 43 Months After Fertility-Preservation Consultation. Pág. 487-495.


20.     Intracranial Antitumor Activity With Encorafenib Plus Binimetinib in Patients With Melanoma Brain Metastases: A Case Series. Pág. 523-530.


21.     Clinical Utility of Hereditary Cancer Panel Testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D Results on Patient Management and Adherence to Provider Recommendations. Pág. 549-558.


22.     Impact of Multimorbidity Subgroups on the Health Care Use of Early Pediatric Cancer Survivors. Pág. 649-658.


23.     Risk Factors for Cardiovascular Disease in 5-Year Survivors of Adolescent and Young Adult Cancer: A Danish Population-Based Cohort Study. Pág. 659-669.


24.     Magnitude of Reduction in Risk of Second Contralateral Breast Cancer With Bilateral Mastectomy in Patients With Breast Cancer: Data From California, 1998 Through 2015. Pág. 959-970.


25.     Nab-Paclitaxel in Older Patients With Non–Small Cell Lung Cancer Who Have Developed Disease Progression After Platinum-Based Doublet Chemotherapy. Pág. 1060-1067.



          JOURNAL OF CLINICAL ONCOLOGY 2020 38 (3)


26.     Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. Pág. 193-202.


27.     Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). Pág. 203-213.


28.     Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study. Pág. 214-222.


29.     Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. Pág. 248-256.


30.     Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 3 2, Phase II Trial. Pág. 257-270.


          JOURNAL OF CLINICAL ONCOLOGY 2020 38 (4)


31.     Impact of Cancer on Employment. Pág. 302-309.


32.     Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs. Pág. 351-358.


33.     Charting the Course: Use of Clinical Pathways to Improve Value in Cancer Care. Pág. 367-371.


34.     Review of Current Policy Strategies to Reduce US Cancer Drug Costs. Pág. 372-379.


35.     Understanding Financial Hardship Among Cancer Survivors in the United States: Strategies for Prevention and Mitigation. Pág. 292-301.


          JOURNAL OF CLINICAL ONCOLOGY 2020 38 (5)


36.     Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. Pág. 388-394.


37.     Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. Pág. 395-405.


38.     Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. Pág. 406-414.


39.     Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Pág. 423-433.